SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astrazeneca Pharma I - Quaterly Results

08 Feb 2022 Evaluate
The total revenue for the quarter ended December 2021 remained nearly unchanged at Rs. 2005.27 millions.A big decline of -45.75% was reported for the quarter ended December 2021 to Rs. 114.20  millions from Rs. 210.52 millions of corresponding previous quarter.Operating Profit reported a sharp decline to 199.98 millions from 336.71 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 2005.27 2002.52 0.14 5736.37 6033.06 -4.92 8135.63 8318.09 -2.19
Other Income 53.31 29.28 82.07 110.73 102.89 7.62 128.41 129.88 -1.13
PBIDT 199.98 336.71 -40.61 592.87 1053.60 -43.73 1483.13 1336.91 10.94
Interest 2.27 2.60 -12.69 7.40 8.11 -8.75 10.93 11.37 -3.87
PBDT 197.71 334.11 -40.82 585.47 1045.49 -44.00 1472.20 1325.54 11.06
Depreciation 35.06 51.10 -31.39 125.43 142.94 -12.25 201.26 185.84 8.30
PBT 162.65 283.01 -42.53 460.04 902.55 -49.03 1270.94 1139.70 11.52
TAX 48.45 72.49 -33.16 123.96 242.31 -48.84 337.90 417.50 -19.07
Deferred Tax 3.69 -4.87 -175.77 -10.19 -20.49 -50.27 -10.38 102.40 -110.14
PAT 114.20 210.52 -45.75 336.08 660.24 -49.10 933.04 722.20 29.19
Equity 50.00 50.00 0.00 50.00 50.00 0.00 50.00 50.00 0.00
PBIDTM(%) 9.97 16.81 -40.69 10.34 17.46 -40.82 18.23 16.07 13.43

Astrazeneca Pharma I Share Price

8508.80 -16.30 (-0.19%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×